NCT03081481View on ClinicalTrials.gov

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

November 28, 2018

Study Completion Date

April 5, 2019

Conditions
Prostate Cancer
Interventions
DRUG

PRX302

Single prostate cancer lesion injected with PRX302

Trial Locations (8)

10016

New York Urology Associates, New York

21204

Chesapeake Urology Associates, Baltimore

34474

Vantage Health, Ocala

76508

Baylor Scott & White Memorial Hospital and Clinic, Temple

Unknown

Princess Alexandra Hospital, Harlow

Imperial College, London

University College Hospital (UCLH), London

University Hospital Southampton, Southampton

All Listed Sponsors
lead

Sophiris Bio Corp

INDUSTRY

NCT03081481 - Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer | Biotech Hunter | Biotech Hunter